Manufacturer’s dossier did not contain suitable data for any therapeutic indication Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act… Read More ›
Bachelor of Arts
Aflibercept in AMD: no proof of added benefit
Manufacturer’s dossier did not contain any usable data for the comparison with ranibizumab The drug aflibercept (trade name: Eylea) has been approved in Germany since November 2012 for the treatment of wet age-related macular degeneration (AMD). In an early benefit… Read More ›
Engineering Evil 